StockDrifts LogoStockDrifts

CHA Biotech 085660

Company
차바이오텍CHA Biotech
Insiders
5
Buys
1
Total Value
₩216M ($150K)
Avg Return
+16.40%
Last Filing
2026-06-25

CHA Biotech (085660) has 1 disclosed insider purchases and 5 disclosed disposals on record, filed by 5 distinct insiders. Together those filings cover ₩216M ($150K) in reported transaction value. The earliest filing StockDrifts holds for CHA Biotech is dated 2025-04-22; the most recent is 2026-06-25. All of it is parsed from DART D001/D002 insider disclosures, the official disclosure system operated by the Financial Supervisory Service (Korea). Across these filings the average return since disclosure is +16.40%, measured from each filing date to the latest available close.

Price & insider activity (12 months)

Recent insider trades

DateTypeSourceInsiderPositionSharesPrice at filingReturnValue
2026-06-25SELLMarket Sell
윤보현
Bohyun Yoon
Managing Director-1.0K₩10,930+4.3%₩11M ($8K)
2026-06-04SELLMarket Sell
장경호
Jang Kyung-ho
Managing Director-500₩12,830+5.0%₩6M ($4K)
2026-05-01BUY신규선임
고정재
fixing material
torture12.5K₩16,900-19.7%₩211M ($147K)
2026-03-31BUY주식매수선택권
양은영
Eunyoung Yang
vice president10.0K₩17,350+2.6%₩174M ($120K)
2026-03-30SELLMarket Sell
양은영
Eunyoung Yang
vice president-2.0K₩18,400+3.3%₩37M ($26K)
2026-03-27SELLMarket Sell
양은영
Eunyoung Yang
vice president-4.1K₩19,680+0.0%₩81M ($56K)
2026-02-05SELLMarket Sell
민영선
Min Young-seon
vice president-2.8K₩21,550+1.4%₩59M ($41K)
2025-07-28BUY신규선임
고경아
Go Kyeong-ah
Assistant Managing Director7.9K₩11,260+88.7%₩89M ($62K)
2025-07-22BUYMarket Buy
전태준
Taejun Jeon
Outside Director1.9K₩11,520+84.5%₩21M ($15K)
2025-06-16SELL기타
정재석
Jaeseok Jeong
Managing Director-341₩10,680-99.0%₩4M ($3K)
2025-06-16SELL기타
양승호
Seungho Yang
Managing Director-341₩10,680-99.0%₩4M ($3K)
2025-06-16SELL기타
민영선
Min Young-seon
vice president-683₩10,680-99.0%₩7M ($5K)
2025-06-16SELL기타
윤보현
Bohyun Yoon
Managing Director-5.3K₩10,680-99.0%₩57M ($40K)
2025-06-16SELL기타
이상규
Lee Sang-gyu
Internal director-5.5K₩10,680-99.0%₩59M ($41K)
2025-06-16SELL기타
양은영
Eunyoung Yang
vice president-3.7K₩10,680-99.0%₩39M ($27K)
2025-06-16SELL기타
박윤상
Park Yun-sang
Internal director-5.5K₩10,680-99.0%₩59M ($41K)
2025-06-16SELL기타
남수연
Sooyeon Nam
president-30.0K₩10,680-99.0%₩320M ($223K)
2025-06-16SELL기타
케이에이치그린
KH Green
--2.8M₩10,680-99.0%₩30.4B ($21.1M)
2025-06-16SELL기타
이동준
Lee Dongjun
vice president-5.7K₩10,680-99.0%₩61M ($42K)
2025-06-16SELL기타
차광렬
Cha Gwang-ryeol
--622.4K₩10,680-99.0%₩6.6B ($4.6M)
2025-06-16SELL기타
한기원
Korea Kiwon
president-15.0K₩10,680-99.0%₩160M ($111K)
2025-06-16SELL기타
나혜정
Na Hye-jeong
Managing Director-2.2K₩10,680-99.0%₩23M ($16K)
2025-06-16SELL기타
김민우
Minwoo Kim
Managing Director-2.0K₩10,680-99.0%₩21M ($15K)
2025-06-16SELL기타
이영진
Youngjin Lee
Managing Director-2.0K₩10,680-99.0%₩21M ($15K)
2025-06-16SELL기타
박번
Park number
president-15.0K₩10,680-99.0%₩160M ($111K)
2025-06-16SELL기타
최석윤
Choi Seok-yoon
Internal director (CEO)-40.0K₩10,680-99.0%₩427M ($297K)
2025-06-16SELL기타
홍연주
Yeonju Hong
Managing Director-8.0K₩10,680-99.0%₩85M ($59K)
2025-06-16SELL기타
배동구
Baedong-gu
Managing Director-2.0K₩10,680-99.0%₩21M ($15K)
2025-06-16SELL기타
강재선
Kang Jae-seon
Managing Director-1.2K₩10,680-99.0%₩13M ($9K)
2025-06-16SELL기타
장경호
Jang Kyung-ho
Managing Director-500₩10,680-99.0%₩5M ($4K)
2025-06-16BUYPROGRAM
장경호
Jang Kyung-ho
Managing Director500₩10,680+99.0%₩5M ($4K)
2025-06-16BUYPROGRAM
나혜정
Na Hye-jeong
Managing Director2.2K₩10,680+99.0%₩23M ($16K)
2025-06-16BUYPROGRAM
김민우
Minwoo Kim
Managing Director2.0K₩10,680+99.0%₩21M ($15K)
2025-06-16BUYPROGRAM
이영진
Youngjin Lee
Managing Director2.0K₩10,680+99.0%₩21M ($15K)
2025-06-16BUYPROGRAM
박번
Park number
president16.7K₩10,680+99.0%₩178M ($124K)
2025-06-16BUYPROGRAM
최석윤
Choi Seok-yoon
Internal director (CEO)44.5K₩10,680+99.0%₩475M ($330K)
2025-06-16BUYPROGRAM
홍연주
Yeonju Hong
Managing Director8.0K₩10,680+99.0%₩85M ($59K)
2025-06-16BUYPROGRAM
배동구
Baedong-gu
Managing Director2.0K₩10,680+99.0%₩21M ($15K)
2025-06-16BUYPROGRAM
강재선
Kang Jae-seon
Managing Director1.3K₩10,680+99.0%₩14M ($10K)
2025-06-16BUYPROGRAM
정재석
Jaeseok Jeong
Managing Director379₩10,680+99.0%₩4M ($3K)
2025-06-16BUYPROGRAM
양승호
Seungho Yang
Managing Director379₩10,680+99.0%₩4M ($3K)
2025-06-16BUYPROGRAM
민영선
Min Young-seon
vice president759₩10,680+99.0%₩8M ($6K)
2025-06-16BUYPROGRAM
윤보현
Bohyun Yoon
Managing Director5.3K₩10,680+99.0%₩57M ($40K)
2025-06-16BUYPROGRAM
이상규
Lee Sang-gyu
Internal director6.1K₩10,680+99.0%₩65M ($45K)
2025-06-16BUYPROGRAM
양은영
Eunyoung Yang
vice president4.1K₩10,680+99.0%₩44M ($30K)
2025-06-16BUYPROGRAM
한기원
Korea Kiwon
president16.7K₩10,680+99.0%₩178M ($124K)
2025-06-16BUYPROGRAM
박윤상
Park Yun-sang
Internal director5.5K₩10,680+99.0%₩59M ($41K)
2025-06-16BUYPROGRAM
남수연
Sooyeon Nam
president33.4K₩10,680+99.0%₩356M ($248K)
2025-06-16BUYPROGRAM
케이에이치그린
KH Green
-3.1M₩10,680+99.0%₩32.7B ($22.7M)
2025-06-16BUYPROGRAM
이동준
Lee Dongjun
vice president5.7K₩10,680+99.0%₩61M ($42K)

Showing the 50 most recent of 77 filings.

Frequently asked questions

Who has been buying CHA Biotech stock?
5 distinct insiders have filed 1 disclosed insider purchases in CHA Biotech (085660), most recently on 2026-06-25. Each filer, their role, the number of shares and the price at filing are listed in the table on this page.
How many insider filings does CHA Biotech have?
CHA Biotech has 1 buy-side and 5 sell-side disclosures on record, covering ₩216M ($150K) in total reported value, spanning 2025-04-22 to 2026-06-25.
Where does StockDrifts get CHA Biotech insider data?
From DART D001/D002 insider disclosures — the official filing system run by the Financial Supervisory Service (Korea). StockDrifts parses each disclosure and matches it to daily price history; the original filings remain available directly from DART.
Do insider buys in Korean stocks predict returns?
Not uniformly. StockDrifts analysed 170,720 share-count changes across 56,930 Korean DART filings using cross-sectional alpha at fixed forward horizons, and found returns concentrated in particular signal tiers rather than in insider buying generally.

Source filings

Every trade listed above is disclosed in DART D001/D002 insider disclosures, filed with the Financial Supervisory Service (Korea). View the original DART filings for CHA Biotech. For how StockDrifts scores these disclosures, see the Korea insider signal tier research, or browse every Korean stock we track.